Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 2)
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two
Sponsor: AstraZeneca
This PHASE3 trial investigates Type 1 Diabetes Mellitus and is currently completed. AstraZeneca leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Mar 2019 — Apr 2019 [monthly]
Completed PHASE3
-
Dec 2018 — Mar 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE3
-
Apr 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .